Featured Press Release

  • 8/9/16 6:50 am EDT

    -- Bendeka market share grows to 80% --
    -- Positive FDA meeting on Ryanodex for EHS --
    -- Eagle purchases Ryanodex royalty --
    -- Announces $75 million share repurchase program --
    -- Q2 EPS increases to $0.84 per basic and $0.80 per diluted, Total Revenue $40.9 million --

    WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or “the Company”) (Nasdaq:EGRX) today announced its financial results for the three- and six-months ended June 30, 2016. Highlights of and subsequent to the second quarter of 2016 include: Business Highlights: Bendeka® total market share rose to 80%, as of Aug 5, 2016; US Food and Drug Administration (“FDA”) determined that no additional human safety andmore